Annotated Study Book - AT3SC002

DS--Disposition

## 'DSTERM = INFORMED CONSENT OBTAINED

AT:	3SC002: Demographic Data and Informed Consent Recordin	ng (DM) [frmDM] INFORMED CONSENT OBTAINED
Den	nographics [sctDM]	
1.*	Date of birth [Date of birth]	[dtmBRTH] (DD/MM/YYYY)   Req
2.* •	Subject signed informed consent on [Date of informed consent]	[dtmIFC] (DD/MM/YYYY)   Req
3.*	Age (calculated) [read-only] [Age]	[numAGE] N3 (years)
4.* •	Sex at birth [Sex at birth]	[IstSXBRTH] [A:M]  Male
5.* •	Race [Race]	[IstRC] [A: REPORTED]
6.*	Ethnicity [Ethnicity]	[IstETHNICITY]  [A:HISPANIC OR LATINO]  Hispanic or Latino  [A:NOT HISPANIC OR LATINO]  Not Hispanic or Latino  [A:NA]  Not Available/Not Reported
7.*	Part in parent study? [Part parent study]	[IstPART]  [A:PART B]
8.*	Did the patient have an interruption between parent study and roll-over to this study?  More than a month between completion of parent study treatment and roll-over to this study will be considered an interruption.  [Subject initiates dosing]	[IstDAYS]     [A:Y]    ○Yes     [A:N]    ○No
9.* •	What is the subject's HIV status? [HIV status]	[IstHIV] [A:POSITIVE] O Positive [A:NEGATIVE] Negative
Will	the Whole Blood Clot Formation test (ROTEM) be performed at this site? [sctD\	YN]
10.*	Will the Whole Blood Clot Formation test (ROTEM) be performed at this site? [ROTEM available]	[IstWBCLT] [A:Y]
Sub	ject Identifiers [sctSUBID]	
11.*	Subject ID (3-digits) [read-only] [Short Subject ID]	[txtSHORTID1] A3
12. •	Site and Subject ID from parent study [Parent study ID]	[txtSUBJI DPS] A7
13.*	Site and Subject ID [hidden] [Site and Subject ID]	[txtSUBJID] A7
14.	For office use only [hidden] [For office use only]	[numEMAIL1] N3
15.	For office use only [hidden] [For office use only]	[numEMAIL2] N3
16.	For office use only [hidden] [For office use only]	[numEMAIL3] N3
	y: [*] = Item is required [♥] = Source verification required te: Source verification or will override any settings made in Central Details.	esigner.
Cod	delist Values Tables: Demographic Data and Informed Conse	ent Recording

Annotated Study Book - AT3SC002 Page 178 of 195

DS--Disposition
RELREC--Related Records

Α	T3SC002: Drug Termination (DRUG TERM) [frmDRUGTERM]		
St	udy Drug Completion / Termination [sctDRUGTERM]		
1.	Date of study drug termination [Date of study drug termination]	[dtmDRUGTERM] (DD/MM/YYYY)   Req	DSTERM='COMPLETED'. If LSTDRUGCOMP_C = 'COMPLETED' then DSTERM='COMPLE
2.	and different in the countries of an if the matient discountions of ALNLATACO and a	[A:DISCONTINUED]	DISTERM=DISCONTINUED.
	Will the action to action to the continue to the continue of t	[A: EMERGENCY]	○Temporary discontinuation due to a regions 在 Temperofe No. 1
3.	Will the patient continue to use commercially available fitusiran? [Will the patient continue to use commercially available fitusiran?]	[IstCOMMERC]  [A: Y] Yes  [A: N] No	
4.	For office use only [hidden] [For office use only]	[numEMAIL1] N3	
5.	For office use only [hidden] [For office use only]	[numEMAIL2] N3	
6.	For office use only [hidden] [For office use only]	[numEMAIL3] N3	

Codelist RefName	Codelist Data Type	Subset	Label	Code	Codelist Item RefName	Data Variable RefName
clCompDisc	String	Jubset	Completed	COMPLETED	citmCompDisc_Comp	IstDRUGCOMP
			Discontinued	DISCONTINUED	citmCompDisc_Disc	
clDISCRS	String		Adverse Event	ADVERSE EVENT	citmDISCRS_AE	IstDISCRS
			Death	DEATH	citmDISCRS_Death	
			Lost to follow-up	LOST TO FOLLOW-UP	citmDISCRS_LostFU	
			Non-Compliance with Study Drug	NON-COMPLIANT	citmDISCRS_NonCompliant	
			Physician Decision	PHYSICIAN DECISION	citmDISCRS_PhysDec	
			Protocol Violation	PROTOCOL VIOLATION	citmDISCRS_PV	
			Study Terminated by Sponsor	STUDY TERMINATED	citmDISCRS_StudyTerm	
			Subject Withdrew Consent	SUBJECT WITHDREW CONSENT	citmDISCRS_WDConsent	
			Other	OTHER	citmDISCRS_Other	
			More than 1 AT measurement <15%	AT	citmDISCRS_AT	
			Temporary discontinuation due to a regional or national emergency	EMERGENCY	citmDISCRS_EMERGENCY	
clYesNo	String		Yes	Υ	citmYesNo_Y	IstCOMMERC

Annotated Study Book - AT3SC002

## DS--Disposition

ΑT	3SC002: Trial Termination (TERM) [frmTERM]		
Tria	al Completion / Discontinuation [sctTERM]		
	Please specify if the subject completed the entire course of the trial as specified in the protocol or if the subject discontinued from the trial early [Completed/Discontinued]	IstCOMPLETED   (Action Microsoft)   (DD/MM/YYYY)   DSTERM=COMPLETE   Completed, date of study completion   Req   / Req   (2015-2023)   Discontinued   Completed   Completed	
2.* ✔	Will the subject roll-over to the next OLE study? [Will the subject roll-over to the next OLE study?]	[IstROLLOVER] [A:Y]	
3.	For office use only [hidden] [For office use only]	[numEMAIL1] N3	
4.	For office use only [hidden] [For office use only]	[numEMAIL2] N3	
5.	For office use only [hidden] [For office use only]	[numEMAIL3] N3	
	ey: [*] = Item is required [ ✔ ] = Source verification required ote: Source verification critical settings made in InForm will override any settings made in Central Des	signer.	

Codelist RefName	Codelist Data Type	Subset	Label	Code	Codelist I tem RefName	Data Variable RefName
clCompDisc	String		Completed	COMPLETED	citmCompDisc_Comp	IstCOMPDISC
			Discontinued	DISCONTINUED	citmCompDisc_Disc	
clDISCRS	String		Adverse Event	ADVERSE EVENT	citmDISCRS_AE	IstDISCRS
			Death	DEATH	citmDISCRS_Death	
			Lost to follow-up	LOST TO FOLLOW-UP	citmDISCRS_LostFU	
			Non-Compliance with Study Drug	NON-COMPLIANT	citmDISCRS_NonCompliant	
			Physician Decision	PHYSICIAN DECISION	citmDISCRS_PhysDec	
			Protocol Violation	PROTOCOL VIOLATION	citmDISCRS_PV	
			Study Terminated by Sponsor	STUDY TERMINATED	citmDISCRS_StudyTerm	
			Subject Withdrew Consent	SUBJECT WITHDREW CONSENT	citmDISCRS_WDConsent	
			Other	OTHER	citmDISCRS_Other	
			More than 1 AT measurement <15%	AT	citmDISCRS_AT	
			Temporary discontinuation due to a regional or national emergency	EMERGENCY	citmDISCRS_EMERGENCY	
clYesNo	String		Yes	Υ	citmYesNo_Y	IstROLLOVER